Cargando…
Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance
SIMPLE SUMMARY: Besides zinc, also iron and copper need to be considered to play a role in the mode of action and resistance development of the anticancer thiosemicarbazone COTI-2 and its derivatives. One of these derivatives (COTI-NMe(2)) was discovered as an interesting new drug candidate with imp...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497102/ https://www.ncbi.nlm.nih.gov/pubmed/36139615 http://dx.doi.org/10.3390/cancers14184455 |
_version_ | 1784794431133581312 |
---|---|
author | Pósa, Vivien Stefanelli, Alessia Nunes, Julia H. Bormio Hager, Sonja Mathuber, Marlene May, Nóra V. Berger, Walter Keppler, Bernhard K. Kowol, Christian R. Enyedy, Éva A. Heffeter, Petra |
author_facet | Pósa, Vivien Stefanelli, Alessia Nunes, Julia H. Bormio Hager, Sonja Mathuber, Marlene May, Nóra V. Berger, Walter Keppler, Bernhard K. Kowol, Christian R. Enyedy, Éva A. Heffeter, Petra |
author_sort | Pósa, Vivien |
collection | PubMed |
description | SIMPLE SUMMARY: Besides zinc, also iron and copper need to be considered to play a role in the mode of action and resistance development of the anticancer thiosemicarbazone COTI-2 and its derivatives. One of these derivatives (COTI-NMe(2)) was discovered as an interesting new drug candidate with improved anticancer activity and resistance profile. ABSTRACT: COTI-2 is currently being evaluated in a phase I clinical trial for the treatment of gynecological and other solid cancers. As a thiosemicarbazone, this compound contains an N,N,S-chelating moiety and is, therefore, expected to bind endogenous metal ions. However, besides zinc, the metal interaction properties of COTI-2 have not been investigated in detail so far. This is unexpected, as we have recently shown that COTI-2 forms stable ternary complexes with copper and glutathione, which renders this drug a substrate for the resistance efflux transporter ABCC1. Herein, the complex formation of COTI-2, two novel terminal N-disubstituted derivatives (COTI-NMe(2) and COTI-NMeCy), and the non-substituted analogue (COTI-NH(2)) with iron, copper, and zinc ions was characterized in detail. Furthermore, their activities against drug-resistant cancer cells was investigated in comparison to COTI-2 and Triapine. These data revealed that, besides zinc, also iron and copper ions need to be considered to play a role in the mode of action and resistance development of these thiosemicarbazones. Moreover, we identified COTI-NMe(2) as an interesting new drug candidate with improved anticancer activity and resistance profile. |
format | Online Article Text |
id | pubmed-9497102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94971022022-09-23 Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance Pósa, Vivien Stefanelli, Alessia Nunes, Julia H. Bormio Hager, Sonja Mathuber, Marlene May, Nóra V. Berger, Walter Keppler, Bernhard K. Kowol, Christian R. Enyedy, Éva A. Heffeter, Petra Cancers (Basel) Article SIMPLE SUMMARY: Besides zinc, also iron and copper need to be considered to play a role in the mode of action and resistance development of the anticancer thiosemicarbazone COTI-2 and its derivatives. One of these derivatives (COTI-NMe(2)) was discovered as an interesting new drug candidate with improved anticancer activity and resistance profile. ABSTRACT: COTI-2 is currently being evaluated in a phase I clinical trial for the treatment of gynecological and other solid cancers. As a thiosemicarbazone, this compound contains an N,N,S-chelating moiety and is, therefore, expected to bind endogenous metal ions. However, besides zinc, the metal interaction properties of COTI-2 have not been investigated in detail so far. This is unexpected, as we have recently shown that COTI-2 forms stable ternary complexes with copper and glutathione, which renders this drug a substrate for the resistance efflux transporter ABCC1. Herein, the complex formation of COTI-2, two novel terminal N-disubstituted derivatives (COTI-NMe(2) and COTI-NMeCy), and the non-substituted analogue (COTI-NH(2)) with iron, copper, and zinc ions was characterized in detail. Furthermore, their activities against drug-resistant cancer cells was investigated in comparison to COTI-2 and Triapine. These data revealed that, besides zinc, also iron and copper ions need to be considered to play a role in the mode of action and resistance development of these thiosemicarbazones. Moreover, we identified COTI-NMe(2) as an interesting new drug candidate with improved anticancer activity and resistance profile. MDPI 2022-09-14 /pmc/articles/PMC9497102/ /pubmed/36139615 http://dx.doi.org/10.3390/cancers14184455 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pósa, Vivien Stefanelli, Alessia Nunes, Julia H. Bormio Hager, Sonja Mathuber, Marlene May, Nóra V. Berger, Walter Keppler, Bernhard K. Kowol, Christian R. Enyedy, Éva A. Heffeter, Petra Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance |
title | Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance |
title_full | Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance |
title_fullStr | Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance |
title_full_unstemmed | Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance |
title_short | Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance |
title_sort | thiosemicarbazone derivatives developed to overcome coti-2 resistance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497102/ https://www.ncbi.nlm.nih.gov/pubmed/36139615 http://dx.doi.org/10.3390/cancers14184455 |
work_keys_str_mv | AT posavivien thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance AT stefanellialessia thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance AT nunesjuliahbormio thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance AT hagersonja thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance AT mathubermarlene thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance AT maynorav thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance AT bergerwalter thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance AT kepplerbernhardk thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance AT kowolchristianr thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance AT enyedyevaa thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance AT heffeterpetra thiosemicarbazonederivativesdevelopedtoovercomecoti2resistance |